|
PT2441467E
(pt)
|
2003-01-31 |
2015-10-12 |
Sinai School Medicine |
Terapia combinada para o tratamento de transtornos associados a uma deficiência proteica
|
|
ES2573498T3
(es)
|
2006-05-16 |
2016-06-08 |
Amicus Therapeutics, Inc. |
Opciones de tratamiento para la enfermedad de Fabry
|
|
US9999618B2
(en)
|
2007-04-26 |
2018-06-19 |
Amicus Therapeutics, Inc. |
Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones
|
|
SI3470077T1
(sl)
|
2008-02-12 |
2020-12-31 |
Amicus Therapeutics, Inc. |
Postopek za napovedovanje odgovora na zdravljenje bolezni s farmakološkim spremljevalcem
|
|
AU2009262670B2
(en)
|
2008-06-26 |
2013-06-20 |
Zevra Denmark A/S |
Use of Hsp70 as a regulator of enzymatic activity
|
|
US8321148B2
(en)
|
2008-10-24 |
2012-11-27 |
Amicus Therapeutics, Inc. |
Multiple compartment dosing model
|
|
US20100119502A1
(en)
*
|
2008-11-11 |
2010-05-13 |
Amicus Therapeutics, Inc. |
Therapy regimens, dosing regimens and stable medicaments for the treatment of pompe disease
|
|
US8940766B2
(en)
|
2009-04-09 |
2015-01-27 |
Amicus Therapeutics, Inc. |
Methods for preventing and/or treating lysosomal storage disorders
|
|
GB0906159D0
(en)
*
|
2009-04-09 |
2009-05-20 |
Summit Corp Plc |
Drug combination for the treatment of proteostatic diseases
|
|
WO2011049737A1
(en)
|
2009-10-19 |
2011-04-28 |
Amicus Therapeutics, Inc. |
Novel compositions for preventing and/or treating lysosomal storage disorders
|
|
WO2011049787A1
(en)
*
|
2009-10-19 |
2011-04-28 |
Amicus Therapeutics, Inc. |
Method for treating alzheimer's disease using pharmacological chaperones to increase the activity of gangliosidases
|
|
SI2490532T1
(sl)
|
2009-10-19 |
2017-03-31 |
Amicus Therapeutics, Inc. |
Novi sestavki za preventivo in/ali zdravljenje degenerativnih motenj centralnega živčnega sistema
|
|
HRP20161223T1
(hr)
*
|
2009-10-27 |
2016-11-18 |
Erytech Pharma |
Pripravak za induciranje specifične imune tolerancije
|
|
JP5739898B2
(ja)
*
|
2009-11-17 |
2015-06-24 |
ベイラー リサーチ インスティテュートＢａｙｌｏｒ Ｒｅｓｅａｒｃｈ Ｉｎｓｔｉｔｕｔｅ |
心疾患マーカーとしての尿中トリアオシルセラミド（ｇｂ３）
|
|
WO2011066352A1
(en)
|
2009-11-27 |
2011-06-03 |
Genzyme Corporation |
An amorphous and a crystalline form of genz 112638 hemitartrat as inhibitor of glucosylceramide synthase
|
|
SI2638152T1
(sl)
*
|
2010-11-08 |
2016-12-30 |
Amicus Therapeutics, Inc. |
Variantni in rekombinantni proteini beta-glukocerebrozidaze s povišano stabilnostjo in povišano ohranjeno katalitično aktivnostjo
|
|
CA2817773A1
(en)
|
2010-11-30 |
2012-06-07 |
Orphazyme Aps |
Methods for increasing intracellular activity of hsp70
|
|
CN103974619B
(zh)
*
|
2011-03-11 |
2017-02-15 |
阿米库斯治疗学公司 |
治疗法布里病的给药方案
|
|
EP2533051A1
(en)
|
2011-06-06 |
2012-12-12 |
Centogene GmbH |
Method for the diagnosis of Gaucher's disease
|
|
KR20200032244A
(ko)
|
2012-03-07 |
2020-03-25 |
아미쿠스 세라퓨틱스, 인코포레이티드 |
폼페병의 치료를 위한 고농도 알파-글루코시다제 조성물
|
|
CA2868459A1
(en)
|
2012-03-27 |
2013-10-03 |
Amicus Therapeutics, Inc. |
Polymorphs of (3r,4r,5s)-5-(difluoromethyl)piperidine-3,4-diol fumarate and uses thereof
|
|
HRP20210398T1
(hr)
*
|
2012-05-03 |
2021-05-28 |
Amicus Therapeutics, Inc. |
Režimi doziranja za liječenje pompeove bolesti
|
|
HK1209625A1
(en)
*
|
2012-07-17 |
2016-04-08 |
Amicus Therapeutics, Inc. |
Alpha-galactosidase a and 1-deoxygalactonojirimycin co-formulation
|
|
US10155027B2
(en)
|
2012-07-17 |
2018-12-18 |
Amicus Therapeutics, Inc. |
Alpha-galactosidase A and 1-deoxygalactonojirimycin co-formulation for the treatment of fabry disease
|
|
US9675627B2
(en)
|
2014-04-14 |
2017-06-13 |
Amicus Therapeutics, Inc. |
Dosing regimens for treating and/or preventing cerebral amyloidoses
|
|
AU2015317447B2
(en)
|
2014-09-15 |
2021-02-25 |
Zevra Denmark A/S |
Arimoclomol formulation
|
|
WO2016054231A1
(en)
|
2014-09-30 |
2016-04-07 |
Amicus Therapeutics, Inc. |
Highly potent acid alpha-glucosidase with enhanced carbohydrates
|
|
GB201508025D0
(en)
|
2015-05-11 |
2015-06-24 |
Ucl Business Plc |
Fabry disease gene therapy
|
|
US10179128B2
(en)
*
|
2015-08-31 |
2019-01-15 |
Amicus Therapeutics, Inc. |
Regimens for treating and preventing lysosomal disorders and degenerative disorders of the central nervous system
|
|
EP3344575B1
(en)
|
2015-09-04 |
2020-04-15 |
SQZ Biotechnologies Company |
Intracellular delivery of biomolecules to cells comprising a cell wall
|
|
KR102510941B1
(ko)
|
2015-12-30 |
2023-03-20 |
아미쿠스 세라퓨틱스, 인코포레이티드 |
폼페병 치료용의 강화된 산 알파-글루코시다제
|
|
JP6438421B2
(ja)
*
|
2016-02-17 |
2018-12-12 |
ファナック株式会社 |
電動機のステータ
|
|
US10227577B2
(en)
|
2016-03-30 |
2019-03-12 |
Amicus Therapeutics, Inc. |
Method for selection of high M6P recombinant proteins
|
|
IL325155A
(en)
|
2016-03-30 |
2026-02-01 |
Amicus Therapeutics Inc |
Formulations containing recombinant acid alpha-glucosidase
|
|
US10898476B2
(en)
|
2016-04-13 |
2021-01-26 |
Orphazyme A/S |
Heat shock proteins and cholesterol homeostasis
|
|
DK3782624T3
(da)
|
2016-04-29 |
2025-12-15 |
Zevra Denmark As |
Arimoclomol til behandling af glucocerebrosidase-associerede lidelser
|
|
JP7602702B2
(ja)
|
2016-05-03 |
2024-12-19 |
ステムセル テクノロジーズ カナダ インコーポレーテッド |
寛容性を誘導するための生体分子の細胞内送達
|
|
NL2017294B1
(en)
|
2016-08-05 |
2018-02-14 |
Univ Erasmus Med Ct Rotterdam |
Natural cryptic exon removal by pairs of antisense oligonucleotides.
|
|
WO2018200618A1
(en)
|
2017-04-25 |
2018-11-01 |
Amicus Therapeutics, Inc. |
Novel compositions for preventing and/or treating degenerative disorders of the central nervous system and/or lysosomal storage disorders
|
|
EP3624831B1
(en)
|
2017-05-15 |
2023-03-29 |
Amicus Therapeutics, Inc. |
Recombinant human acid alpha-glucosidase
|
|
CA3224537C
(en)
*
|
2017-05-30 |
2025-09-09 |
Amicus Therapeutics, Inc. |
USE OF MIGALASTAT IN THE TREATMENT OF PATIENTS WITH FABRY DISEASE AND RENAL FAILURE
|
|
PT4324522T
(pt)
|
2017-05-30 |
2026-03-13 |
Amicus Therapeutics Inc |
Métodos de tratamento de pacientes com fabry tendo insuficiência renal
|
|
CA3090496C
(en)
|
2018-02-06 |
2024-03-26 |
Amicus Therapeutics, Inc. |
Use of migalastat for treating fabry disease in pregnant patients
|
|
EP4282472A3
(en)
|
2018-08-20 |
2024-02-21 |
Amicus Therapeutics, Inc. |
Methods of treating fabry disease in patients having a mutation in the gla gene
|
|
EP3894864A2
(en)
*
|
2018-12-10 |
2021-10-20 |
Denali Therapeutics Inc. |
Lysosomal storage disorder biomarkers and methods of use thereof
|
|
AR120055A1
(es)
*
|
2019-06-11 |
2022-02-02 |
Amicus Therapeutics Inc |
Métodos para tratar la enfermedad de fabry en pacientes que tienen insuficiencia renal
|
|
EP3851105B1
(en)
|
2019-08-07 |
2026-03-04 |
Amicus Therapeutics, Inc. |
Migalastat for use in treating fabry disease in patients having a mutation in the gla gene
|
|
KR20230128462A
(ko)
|
2020-11-19 |
2023-09-05 |
제브라 덴마크 에이/에스 |
아리모클로몰 시트레이트 및 이의 중간체를 제조하기 위한 공정
|
|
US11623916B2
(en)
|
2020-12-16 |
2023-04-11 |
Amicus Therapeutics, Inc. |
Highly purified batches of pharmaceutical grade migalastat and methods of producing the same
|